ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.12, Zacks reports.
ProMIS Neurosciences Trading Up 5.2 %
Shares of NASDAQ PMN traded up $0.04 during trading hours on Tuesday, reaching $0.73. The stock had a trading volume of 73,038 shares, compared to its average volume of 42,402. The business’s fifty day moving average price is $0.82 and its two-hundred day moving average price is $0.96. The firm has a market cap of $23.93 million, a price-to-earnings ratio of -7.32 and a beta of 0.58. ProMIS Neurosciences has a 52-week low of $0.62 and a 52-week high of $2.61.
Analyst Ratings Changes
Separately, Guggenheim reiterated a “buy” rating and issued a $6.00 target price on shares of ProMIS Neurosciences in a research note on Tuesday.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Stories
- Five stocks we like better than ProMIS Neurosciences
- How to Calculate Options Profits
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- What Are Dividends? Buy the Best Dividend Stocks
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What is a buyback in stocks? A comprehensive guide for investors
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
